MedTrace Logo

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

NCT05010629 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-05-31

No results posted yet for this study

Summary

This trial is investigating an intravenous (IV) medication called 9-ING-41 in combination with chemotherapy (carboplatin) for the treatment of advanced salivary gland cancers.

The names of the study drug(s) involved in this study are:

* 9-ING-41 (a GSK-3β inhibitor)
* Carboplatin chemotherapy

Conditions

  • Salivary Gland Cancer
  • Recurrent Salivary Gland Cancer
  • Metastatic Cancer
  • Adenoid Cystic Carcinoma

Interventions

DRUG

9-ING-41

Intravenous infusion

DRUG

Carboplatin

Intravenous infusion

Sponsors & Collaborators

  • Actuate Therapeutics Inc.

    collaborator INDUSTRY

  • Glenn J. Hanna

    lead OTHER

Principal Investigators

  • Glenn J Hanna, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-14
Primary Completion
2025-02-14
Completion
2027-04-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05010629 on ClinicalTrials.gov